From pipeline to patient: new developments in cystic fibrosis therapeutics

Bibliography

• O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373(9678):1891-904
   PubMed Web of Science ®Google Scholar
• CF Trust. UK CF registry annual data report 2010. CF Trust, Bromley, UK; 2010
   Google Scholar
• Dodge JA, Lewis PA, Stanton M, Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J 2007;29(3):522-6
   PubMed Web of Science ®Google Scholar
• Frerichs C, Smyth A. Treatment strategies for cystic fibrosis: what's in the pipeline? Expert Opin Pharmacother 2009;10(7):1191-202
   PubMed Web of Science ®Google Scholar
• Pezzulo AA, Tang XX, Hoegger MJ, Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012;487(7405):109-13
   PubMed Web of Science ®Google Scholar
• Corey M. Power considerations for studies of lung function in cystic fibrosis. Proc Am Thorac Soc 2007;4(4):334-7
   Google Scholar
• Schuler D, Sermet-Gaudelus I, Wilschanski M, Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros 2004;3(Suppl 2):151-5
   Google Scholar
• Durmowicz AG, Witzmann KA, Rosebraugh CJ, Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest 2013;143(1):14-18
   PubMed Web of Science ®Google Scholar
• Mott LS, Park J, Murray CP, Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. Thorax 2012;67(6):509-16
   PubMed Web of Science ®Google Scholar
• Thomas KE, Parnell-Parmley JE, Haidar S, Assessment of radiation dose awareness among pediatricians. Pediatr Radiol 2006;36(8):823-32
   PubMedGoogle Scholar
• O'Connell OJ, McWilliams S, McGarrigle A, Radiologic imaging in cystic fibrosis: cumulative effective dose and changing trends over 2 decades. Chest 2012;141(6):1575-83
   PubMed Web of Science ®Google Scholar
• Fuchs SI, Gappa M. Lung clearance index: clinical and research applications in children. Paediatr Respir Rev 2011;12(4):264-70
   Google Scholar
• Aurora P, Stanojevic S, Wade A, Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2011;183(6):752-8
   PubMed Web of Science ®Google Scholar
• Konstan MW, Flume PA, Kappler M, Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10(1):54-61
   PubMed Web of Science ®Google Scholar
• Schuster A, Haliburn C, Doring G, Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2012; doi:10.1136/thoraxjnl-2012-202059
   Google Scholar
• Dupont L, Minic P, Fustic S, A randomized placebo-controlled study of nebulized liposomal amikacin (Arikace(TM)) in the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Cystic Fibrosis 2008;7(Suppl 2):S26-6
   Google Scholar
• Okusanya OO, Bhavnani SM, Hammel J, Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53(9):3847-54
   PubMed Web of Science ®Google Scholar
• Geller DE, Flume PA, Staab D, Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183(11):1510-16
   PubMed Web of Science ®Google Scholar
• Trapnell BC, McColley SA, Kissner DG, Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012;185(2):171-8
   PubMed Web of Science ®Google Scholar
• Stick SM, Sly PD. Exciting new clinical trials in cystic fibrosis: infants need not apply. Am J Respir Crit Care Med 2011;183(12):1577-8
   Google Scholar
• Rosenfeld M, Emerson J, Williams-Warren J, Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139(3):359-65
   PubMed Web of Science ®Google Scholar
• Bilton D, Robinson P, Cooper P, Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011;38(5):1071-80
   PubMed Web of Science ®Google Scholar
• Aitken ML, Bellon G, De Boeck K, Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185(6):645-52
   PubMed Web of Science ®Google Scholar
• Accurso FJ, Moss RB, Wilmott RW, Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011;183(5):627-34
   Google Scholar
• Ratjen F, Durham T, Navratil T, Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J Cyst Fibros 2012;11(6):539-49
   PubMed Web of Science ®Google Scholar
• Wilschanski M, Miller LL, Shoseyov D, Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011;38(1):59-69
   PubMed Web of Science ®Google Scholar
• Rowe S, Sermet-Gaudelus I, Konstan MW, Results of the phase 3 study of ataluren in nonsense mutation cystic fibrosis (NMCF) [abstract]. Pediatric Pulmonology 2012;47(Suppl 35):290
   Google Scholar
• Ramsey BW, Davies J, McElvaney NG, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365(18):1663-72
   PubMed Web of Science ®Google Scholar
• Flume PA, Liou TG, Borowitz DS, Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest 2012;142(3):718-24
   PubMed Web of Science ®Google Scholar
• Boyle MP, Bell S, Konstan M, The investigational CFTR corrector, VX809 (lumacaftor) co-administered with the oral potentiator ivacaftor improved CFTR and lung function in F508DEL homozygous patients: phase II study results. Pediatric Pulmonology 2012;47(Supplt 35):315
   Google Scholar
• Norez C, Noel S, Wilke M, Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett 2006;580(8):2081-6
   PubMed Web of Science ®Google Scholar
• Leonard A, Lebecque P, Dingemanse J, A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference. J Cyst Fibros 2012;11(3):231-6
   PubMed Web of Science ®Google Scholar
• Minicucci L, Haupt M, Casciaro R, Slow-release insulin in cystic fibrosis patients with glucose intolerance: a randomized clinical trial. Pediatr Diabetes 2012;13(2):197-202
   PubMed Web of Science ®Google Scholar
• Stalvey MS, Anbar RD, Konstan MW, A multi-center controlled trial of growth hormone treatment in children with cystic fibrosis. Pediatr Pulmonol 2012;47(3):252-63
   Google Scholar
• Haworth CS, Sharples L, Hughes V, Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. J Cyst Fibros 2011;10(6):470-6
   Google Scholar
• Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 2012;4:CD002010
   Google Scholar
• Borowitz D, Stevens C, Brettman LR, International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients. J Cyst Fibros 2011;10(6):443-52
   Google Scholar